Exhibit 16.1
| Deloitte LLP | ||||
| 2800 - 1055 Dunsmuir Street | ||||
| 4 Bentall Centre | ||||
| P.O. Box 49279 | ||||
| Vancouver BC V7X 1P4 | ||||
| Canada | ||||
| Tel: 604-669-4466 | ||||
Fax: 604-685-0395 www.deloitte.ca | ||||
February 4, 2013
Securities and Exchange Commission
100 F Street, NE
Washington DC 20549-7561
USA
Dear Sirs:
| Subject: | Celator Pharmaceuticals, Inc. | |
| SEC File No. 000-54852 |
On January 30, 2013, our appointment as auditor for Celator Pharmaceuticals, Inc. ceased. We have read Celator Pharmaceuticals, Inc.’s statements included under Item 4.01 of its Form 8-K dated February 4, 2013 and based on our knowledge of such information at this time, agree with such statements, insofar as they apply to us.
Very truly yours,
Independent Registered Chartered Accountants
Membre de / Member of Deloitte Touche Tohmatsu Limited